. 2020 Aug 19;18(2):307–317. doi: 10.1038/s41423-020-0519-3

Table 3.

IL-1/IL-36 targets and treatments for pustular psoriasis that are under preclinical and clinical trials

Treatment/target	Pustular psoriasis subtype: results	Trial
Gevokizumab/IL-1β	GPP: beneficial¹⁰⁹	Case report
Canakinumab/IL-1β	GPP: beneficial¹¹⁰	Case report
Canakinumab/IL-1β	PPP: unresponsive¹¹¹	Case report
Anakinra/IL-1RA	GPP: beneficial⁸⁶	Case report
Anakinra/IL-1RA	PPP: partial response¹³⁷	Case report
Spesolimab/IL-36R	GPP: beneficial^{54, 138}	Phase III clinical trial
Spesolimab/IL-36R	PPP: beneficial¹³⁹	Phase II clinical trial
ANB019/IL-36R	GPP: beneficial¹⁴⁰	Phase II clinical trial
ANB019/IL-36R	PPP: beneficial¹⁴¹	Phase II clinical trial

GPP generalized pustular psoriasis, PPP palmoplantar pustular psoriasis